Magazine Article | February 1, 2021

CEO Q&A: Mary Szela

Source: Life Science Leader

By Dan Schell, Editorial Director, Life Science Leader

Mary Szela is president and CEO of TriSalus Life Sciences, an emerging immuno-oncology company developing treatments for patients with solid tumors. She has more than 30 years of biopharma experience, including spending 25 years at Abbott, where she held ascending management positions, including president of the company’s $8 billion U.S. pharmaceutical business. During the last seven years, she has held CEO positions at Melinta Pharmaceuticals, Novelion Therapeutics, and now TriSalus. With that kind of experience, we asked her to participate in the following Q&A to offer our readers some valuable insights about what it takes to transition from Big Pharma to a CEO position at a smaller biotech.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: